login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
DOGWOOD THERAPEUTICS INC (DWTX) Stock News
USA
- NASDAQ:DWTX -
US92829J2033
-
Common Stock
6.0207
USD
+0.14 (+2.39%)
Last: 10/27/2025, 10:25:51 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
DWTX Latest News, Press Relases and Analysis
All
Press Releases
13 days ago - By: ACCESS Newswire
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
20 days ago - By: ACCESS Newswire
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
25 days ago - By: Benzinga
- Mentions:
BOLT
GOVX
SCYX
LPTX
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
25 days ago - By: Benzinga
- Mentions:
CIGL
BOLT
UFG
EFX
...
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket
a month ago - By: Stocktwits
- Mentions:
VXF
Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug
a month ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
2 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
3 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
3 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
3 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
5 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
6 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics Announces First Quarter 2025 Financial Results
7 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
7 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
7 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
7 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
8 months ago - By: Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Please enable JavaScript to continue using this application.